SEC Company Response from MiNK Therapeutics, (INKT) — Oct 12, 2021
MiNK Therapeutics, Inc.
Date: Oct. 12, 2021 · CIK: 0001840229 · Accession: 0001193125-21-296966
AI Filing Summary & Sentiment
File numbers found in text: 333-259503
Show Raw Text
CORRESP 1 filename1.htm CORRESP MiNK Therapeutics, Inc. 149 Fifth Avenue, Suite 500 New York, NY 10010 October 12, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius Re: MiNK Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-259503) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, MiNK Therapeutics, Inc., a Delaware corporation (the “Company”), hereby requests that the effective date for the registration statement referred to above be accelerated so that it will be declared effective at 4:00 p.m. Eastern Time on October 14, 2021, or as soon as possible thereafter. The Company hereby authorizes Zachary Blume of Ropes & Gray LLP, counsel to the Company, to orally modify or withdraw this request for acceleration. Please call Zachary Blume of Ropes & Gray LLP, counsel to the Company, at (617) 951-7663, as soon as the registration statement has been declared effective. [Signature page follows] Very truly yours, MINK THERAPEUTICS, INC. By: /s/ Jennifer S. Buell Name: Jennifer S. Buell Title: President and Chief Executive Officer [Signature Page to Acceleration Request]